Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Human+ Fund is an early-stage investment fund based in Amsterdam, Netherlands, established to accelerate the translation of innovative biomedical research into viable products and treatments. Founded by Clayton Heijman and Frank de Man, the fund collaborates with the Netherlands Organisation for Health Research (ZonMw), Reumafonds, and two family offices. This collaboration aims to address the stagnation in the development of new biomedical products.
The fund currently focuses on early-stage investments in Europe, specifically targeting the biotech and healthcare sectors. Human+ Fund has developed a unique co-financing model that bridges the gap between public and private funding, enabling high-potential research projects to receive the necessary financial support. The fund's mission is to create a significant impact for patients while also generating returns for its investors.
Human+ Fund invests in early-stage companies across the pre-seed, seed, seed+, and Series A stages. The fund specifically targets sectors such as biomedical technology, diagnostics, and pharmaceutical products. By employing a co-financing model, Human+ Fund aims to support innovative product development that addresses critical healthcare challenges.
The fund seeks to identify and invest in projects that demonstrate high potential for success in the biomedical field. Human+ Fund looks for founders who are committed to advancing their research into practical applications that can improve patient outcomes. The investment strategy emphasizes collaboration with other funding sources to maximize the impact of each investment.
Human+ Fund has built a notable portfolio of companies focused on advancing healthcare solutions. Key portfolio companies include:
These companies exemplify the fund's commitment to supporting innovative solutions in the biomedical sector.
Clayton Heijman: Founder of Human+ Fund, Heijman has a background in biomedical research and investment, focusing on translating scientific innovations into marketable products.
Frank de Man: Co-Director and Fund Manager, de Man has extensive experience in managing investment funds and has a strong focus on healthcare innovation.
Peter Sijmons: Fund Team Member, Sijmons contributes expertise in biomedical technology and investment strategies.
Connie Lamphen: Co-Director, Lamphen brings a wealth of knowledge in healthcare investments and project management.
What are the investment criteria for Human Plus Fund?
Human+ Fund focuses on early-stage investments in the biotech and healthcare sectors, specifically in biomedical technology, diagnostics, and pharmaceutical products. The fund looks for projects that demonstrate high potential for success and can bridge the gap between public and private funding.
How can I pitch my startup to Human Plus Fund?
Founders can reach out through the fund's website or LinkedIn page. A detailed pitch deck that outlines the innovative aspects of the product, market potential, and team background is recommended.
What makes Human Plus Fund different from other investors?
The fund employs a unique co-financing model that allows it to collaborate with public and private funding sources, which enhances the financial support available for high-potential biomedical research projects.
What is the geographic focus of Human Plus Fund?
Human+ Fund primarily invests in early-stage companies located in Europe, particularly those that are developing solutions in the biotech and healthcare sectors.
What is the typical check size for investments?
While specific check sizes are not disclosed, Human+ Fund invests in pre-seed, seed, seed+, and Series A rounds, indicating a flexible approach to funding based on the needs of the startup.
What kind of support can portfolio companies expect?
Portfolio companies receive not only financial backing but also strategic guidance and access to a network of industry experts, which can help accelerate their growth and development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.